viaskin - search results
If you're not happy with the results, please do another search
OIT is a Therapy, Not an Ideology
The decisions we all face as patients and caretakers depend on the individual, their allergies, their lifestyles and myriad other factors.
Non-Profit Institute to Review Benefits of Commercial, Private Practice Immunotherapies for Peanut Allergy
An independent review of the value, costs and effectiveness of Viaskin Peanut, AR101, and private practice peanut OIT.
Milk and Peanut Clinical Trial Advances
Announcements regarding two food allergy therapies that are in or advancing toward clinical trials were made yesterday.
DBV Completes Phase III Study of Peanut Patch
The phase III trial was designed to assess the safety and routine clinical use of Viaskin Peanut.
Peanut Patch Phase III Enrollment Ends, Results Expected Toward End of 2017
The study received higher-than-expected patient demand.
Study: Peanut Immunotherapy Significantly Reduces Risks Due to Cross-Contact in Common Packaged Foods
The study model used common packaged foods such as cookies, ice cream, and doughnuts as references.
Study: EPIT (Skin Patch) Therapy Provides Sustained Protection Against Anaphylaxis
The unique immune communication between skin and gastrointestinal tract can be used to generate long-lasting protection from food allergies.
Nestlé Partners with DBV to Develop Milk Allergy Test
The world's largest food business forays into allergy diagnostic services to help sell infant formula.
Breakthrough Food Allergy Therapies and the Big Business Behind Them
What it means to be a breakthrough therapy, who is developing them, how they work, and the (big) business drivers behind them.
Peanut Patch Receives FDA's Breakthrough Therapy Designation
The Viaskin Peanut patch received the BT designation after a positive Phase IIb trial.
